Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05345197 · ClinicalTrials.gov registry record · Phase 2
Emicizumab in Patients With Acquired Hemophilia A
A Phase 2 study of Acquired Hemophilia A, sponsored by University of Washington.
- Active
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
- 16
- Study locations
NCT05345197 is a Phase 2 study of Acquired Hemophilia A that is active but no longer recruiting, run by University of Washington. The registered enrollment target is 51 participants. The trial reports 16 study locations across 15 states.
The verdict
NCT05345197, a Phase 2 study of Acquired Hemophilia A, is active but no longer recruiting, sponsored by University of Washington.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
- 16
- Study locations
Study Summary
This is a phase II multicenter open-label, single-arm prospective study to evaluate the efficacy of prophylactic emicizumab administered on a scheduled basis to prevent bleeds in patients with acquired hemophilia A (AHA).
Conditions Studied
Interventions
- DRUG emicizumab
Study Locations (16)
Pennsylvania
- Penn Blood Disorders Program, Hospital of the University of Pennsylvania - Philadelphia
- Hemophilia Center of Western Pennsylvania - Pittsburgh
California
- UCSD Hemophilia and Thrombosis Treatment Center - San Diego
District of Columbia
- Georgetown University - Washington D.C.
Georgia
- Emory University - Atlanta
Illinois
- Bleeding and Clotting Disorders Institute - Peoria
Indiana
- Indiana Hemophilia and Thrombosis Center, Inc. - Indianapolis
Louisiana
- Tulane University - New Orleans
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2022-08-31 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05345197
The ClinicalTrials.gov registry entry for NCT05345197 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acquired Hemophilia A appearing as the primary indexed condition, and to 1 intervention - of which emicizumab is the first listed.
NCT05345197 reports 16 study locations spanning 15 distinct geographic areas - top geographies include Pennsylvania, California, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT05345197 about?
NCT05345197 is a clinical study titled "Emicizumab in Patients With Acquired Hemophilia A". This is a phase II multicenter open-label, single-arm prospective study to evaluate the efficacy of prophylactic emicizumab administered on a scheduled basis to prevent bleeds in patients with acquired hemophilia A (AHA).
What is the current status of trial NCT05345197?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2022-08-31. Estimated completion is 2026-12.
What conditions does trial NCT05345197 study?
This clinical trial studies the following conditions: Acquired Hemophilia A.
What interventions are being tested in trial NCT05345197?
The interventions under investigation include: emicizumab (DRUG).
Who is sponsoring clinical trial NCT05345197?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05345197 being conducted?
This trial has 16 study locations across California, District of Columbia, Georgia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.